GTBP GT Biopharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 109657 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-309.0%
TTM EPS YoY-14.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-1,446.5%
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets—
Debt / equity0.00x
Current ratio4.14x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.28x
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.71M | $1.05M | $413,000 | $1.38M | $634,000 | $363,000 | $1.10M | $1.93M |
| SG&A expense | $1.80M | $3.46M | $2.44M | $4.22M | $2.75M | $1.15M | $833,000 | $1.83M |
| Operating income | -$3.51M | -$4.51M | -$2.85M | -$5.59M | -$3.38M | -$1.51M | -$1.93M | -$3.76M |
| Interest expense | $63,000 | $64,000 | $63,000 | — | — | — | — | — |
| Net income | -$3.53M | -$4.52M | -$2.83M | -$23.03M | $8.30M | -$30.17M | -$776,000 | -$3.77M |
| EPS (basic) | -1.98 | -0.12 | -0.11 | — | 25.99 | -10.92 | -0.33 | — |
| EPS (diluted) | -1.98 | -0.12 | -0.11 | — | 25.99 | -10.92 | -0.33 | — |
| Weighted avg. shares (diluted) | 1.81M | 38.82M | 30.28M | — | 157,629 | 2.77M | 2.35M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $9.92M | $4.96M | $8.92M | $6.81M | $2.62M | $5.32M | $2.46M | $4.04M |
| Current assets | $10.57M | $5.79M | $10.00M | $8.11M | $4.32M | $7.12M | $2.66M | $4.23M |
| Total assets | — | — | — | $8.11M | $4.32M | $7.12M | — | $4.23M |
| Current liabilities | $2.77M | $2.22M | $2.42M | $2.32M | $1.32M | $31.04M | $3.64M | $5.90M |
| Total liabilities | $2.77M | $2.22M | $2.42M | $2.32M | $1.32M | $31.04M | $3.64M | $5.90M |
| Shareholders' equity | $7.80M | $3.57M | $7.58M | $5.79M | $3.00M | -$25.88M | -$980,000 | -$1.67M |
| Shares outstanding | 2.06M | 44.67M | 35.18M | 1.02M | 6.05M | 3.27M | 2.54M | 2.23M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.64M | -$4.26M | -$2.47M | -$4.02M | -$3.68M | -$3.01M | -$2.20M | -$2.47M |
| Investing cash flow | — | — | — | — | — | — | — | $1,000 |
| Financing cash flow | $7.60M | $297,000 | $4.58M | $8.30M | $977,000 | $5.88M | $616,000 | $0 |
| Stock-based compensation | — | — | $46,000 | $46,000 | $379,000 | $4,000 | $3,000 | $8,000 |
| Dividends paid | — | — | — | $144,000 | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.